Regenexx Is Committed to Innovation.
The pioneer in using bone marrow concentrate treatments for orthopedic conditions, Regenexx® has always been at the forefront of developing and refining non-surgical procedures. We not only create and perform these procedures, but we also have published 44%* of the world’s research on the subject.
We have more than a decade’s worth of data on our procedures, and our patients are participants in the largest database of an orthopedic patient population who were treated with bone marrow concentrate. Because of our long history in the field and commitment to research, we have more data than any of our peer interventional orthopedics providers.
Largest Bone Marrow Concentrate Safety Paper Ever Published
With 2,372 patients studied, in 2016, Regenexx produced the largest and most in-depth paper on bone marrow concentrate safety in the world. Also notable about the published piece is the length of the study’s follow-up period for a cohort of patients this size and the comprehensiveness of the reported residual issues. Plus, the data came from several treatment facilities with every major complaint investigated by a panel of five scientists and physicians wholly unaffiliated with Regenexx.
Not ones to rest on our laurels, we remain committed to finding fresh methods and approaches with the use of our research and development laboratory. We apply our findings to our work with our patients and have done so for more than a decade. No other interventional orthopedics provider has this history or such a deep database.
We openly share the results from our extensive and transparent outcomes database with the public and our peers so that our patients and their physicians can come to an educated decision about their treatment plan.
Besides treating our patients, Regenexx is at the forefront of Interventional Orthopedics. We have filed several patents for the biologic treatments and devices we have developed, making us unique among our peer clinics.